Anesthesia Coding Alert

Bringing awareness through coding accuracy and education.

October brings renewed focus to breast cancer awareness. For medical coders and other healthcare business professionals, it’s an opportunity to deepen our understanding of the complex diagnostic and procedural codes surrounding breast cancer care.

With approximately 316,950 new cases of invasive breast cancer expected in 2025, according to the American Cancer Society, getting the coding right and understanding the care behind it play key roles in helping patients get the care they need covered under their insurance.

In this article, we’ll review breast cancer detection, types of breast cancer, treatment options, and coding for both diagnoses and procedures.

Recognizing Breast Cancer Warning Signs

Breast cancer can present with a variety of warning signs beyond a noticeable lump. These may include skin changes such as dimpling, redness, swelling, or a peau d’orange appearance; nipple changes like spontaneous discharge, retraction, inversion, or persistent scaling; and shifts in breast texture, firmness, or symmetry. While breast pain alone is often benign, new or persistent pain on one side, especially when combined with other symptoms, should prompt further evaluation. Attention to these signs supports timely diagnosis and appropriate follow-up care.

Recognizing the Spectrum of Breast Cancer

No two breast cancer diagnoses are alike. Variations in hormone receptor status, histologic type, genetic mutations, and disease stage lead to vastly different treatment paths and prognoses. For coders, recognizing this variability is critical to choosing the correct codes. For patients, it reinforces the need for personalized care and precise communication among all members of their care team.

Types of Breast Cancer

There are multiple and various histologic types of breast cancer, each with distinct characteristics and treatment implications.

Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer where abnormal cells are found in the lining of a milk duct but have not spread beyond the duct into surrounding breast tissue. DCIS accounts for about 15-20 percent of all breast cancers detected through screening and is considered stage 0. While not immediately life-threatening, it carries a risk of progressing to invasive cancer if left untreated.

Invasive ductal carcinoma (IDC) accounts for approximately 80 percent of all breast cancers. IDC begins in the milk ducts and spreads to surrounding breast tissue, potentially metastasizing to lymph nodes and distant organs.

Invasive lobular carcinoma (ILC) comprises about 10-15 percent of invasive breast cancers. Beginning in the lobules (milk-producing glands), ILC grows in single-file lines through breast tissue, making it more difficult to detect on imaging studies compared to IDC.

Inflammatory breast cancer represents an aggressive form accounting for 1-5 percent of breast cancers. This rare type blocks lymph vessels in breast skin, causing swelling, redness, and warmth. The breast may appear infected, but antibiotics do not resolve the symptoms.

Triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and HER2 protein expression. Representing about 10-15 percent of breast cancers, this subtype tends to be more aggressive and occurs more frequently in younger women and women of African American descent.

HER2-positive breast cancers overexpress the HER2 protein, comprising about 15-20 percent of breast cancers. While historically associated with poor prognosis, targeted therapies have significantly improved outcomes for patients with HER2-positive disease.

Hormone receptor-positive breast cancers express estrogen receptors and/or progesterone receptors. These cancers, representing about 70-80 percent of all breast cancers, typically respond well to hormone therapy treatments that block th

These categories are not mutually exclusive. Invasive ductal carcinoma is classified by tissue type, while hormone receptor–positive cancers are classified by receptor status. Many IDC tumors are also hormone receptor–positive, so the percentages overlap rather than add up.

The Critical Role of Screening

Regular screening remains one of the most effective tools for reducing breast cancer mortality. The American College of Radiology and the National Comprehensive Cancer Network recommend that women at average risk begin annual screening mammograms at age 40. This recommendation is supported by radiology organizations due to strong evidence that consistent screening improves early detection and outcomes.

Breast self-exams remain an important component of early detection. Performing monthly self-exams helps individuals become familiar with the normal look and feel of their breasts, making it easier to recognize new lumps, skin changes, or other abnormalities. Early recognition of these signs can lead to timely medical evaluation and diagnosis. The free “Feel For Your Life” mobile application provides monthly reminders and guided instructions for breast self-examinations.

Women with dense breast tissue may benefit from supplemental screening. Automated breast ultrasound (ABUS), reported with 76641 (Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete), is a Food and Drug Administration-approved technology used in conjunction with screening mammography to improve cancer detection in dense breasts. ABUS is noninvasive, does not involve radiation, and provides additional imaging detail that may reveal cancers not visible on mammograms alone.

Women at higher risk, including those with a family history of breast cancer, known BRCA mutations, or prior chest radiation, may require earlier and more intensive screening such as annual breast MRI, reported with 77046-77049, in addition to mammography.

Screening mammography, reported with 77067 (Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed), is used for asymptomatic patients as part of routine preventive care. Diagnostic mammography, reported with 77065 (Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral) for a unilateral exam or 77066 (Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral) for a bilateral exam, is used when a patient presents with symptoms such as a lump, nipple discharge, or breast pain.

Understanding Breast Cancer Diagnosis Codes

ICD-10-CM provides specific categories for breast cancer diagnoses, with careful attention to laterality and anatomical location. Primary malignant neoplasms of the breast fall under category C50.- (Malignant neoplasm of breast), with site-specific subcategories that require precise documentation for optimal coding accuracy and reimbursement. It’s important to note that the diagnosis codes do not specify histologic type or hormone receptor status; these clinical details are documented separately in the medical record and do not affect the primary diagnosis code selection.

Coding best practice dictates using the most specific anatomical location codes rather than defaulting to unspecified site codes. When documentation allows, coders should utilize precise codes that specify laterality and quadrant location.

The unspecified site codes (C50.911, C50.912, C50.919) should only be used when clinical documentation genuinely lacks specific anatomical location information. Encouraging providers to document precise tumor location, laterality, and quadrant not only improves coding accuracy but also supports better clinical communication and treatment planning.

Male breast cancer, though rare, requires its own coding considerations. Pay attention to the code descriptors as they are broken out by female and male breast.

Carcinoma In Situ Coding

Carcinoma in situ refers to abnormal cells that are confined to the ducts or lobules of the breast and have not invaded surrounding tissue. While not yet invasive cancer, it requires careful monitoring and treatment due to its progression potential. Look to category D05 (Carcinoma in situ of breast) for lobular, intraductal, other specified, and unspecified carcinoma in situ of the breast codes.

Benign Breast Neoplasms

Benign breast neoplasms are non-cancerous tumors, such as fibroadenoma or papilloma, that do not invade surrounding tissue or metastasize but may still require evaluation or removal depending on size, symptoms, or imaging findings. The codes for benign breast conditions are in category D24 (Benign neoplasm of breast).

Hormone Receptor Status Coding

When hormone receptor status is documented, use additional codes to identify estrogen, progesterone, and other hormone receptor status. Hormone receptor status codes are Z17.0-Z17.421 (includes estrogen receptor positive, estrogen receptor negative, progesterone receptor positive, progesterone receptor negative, and HER2 receptor status).

Skin Cancer of Breast

Malignant neoplasms of skin of breast require specific coding. Look to skin of breast malignancy (basal cell, squamous cell, other specified, and unspecified) codes C44.501-C44.591.

Risk Assessment and History Codes

Code also risk assessment and history codes, such as genetic susceptibility to malignant neoplasm of breast (Z15.01) and family history of breast cancer (Z80.3), when documented. Common clinical presentation codes should be selected based on the documented signs and symptoms such as breast lumps, nipple changes, discharge, gynecomastia, or abnormal imaging findings.

Breast Biopsy Procedures

Breast cancer diagnosis is a multi-step process that begins with imaging and tissue sampling, often performed by a radiologist using percutaneous image-guided biopsy techniques. Once a sample is collected, it is sent to a pathology lab for tissue analysis to determine histologic type, grade, and receptor status. Based on these findings, patients are typically referred to a general surgeon or a surgical oncologist who specializes in breast cancer to discuss surgical treatment options. If reconstructive surgery is being considered, a plastic surgeon may also be involved.

Accurate tissue diagnosis forms the foundation of breast cancer treatment, making biopsy procedures essential to the diagnostic process. Several biopsy techniques exist, each with specific CPT^® codes that reflect the imaging and approach used: percutaneous image-guided breast biopsies (19081-19086), open incisional breast biopsy (19101), percutaneous cryosurgical ablation of a fibroadenoma (19105), open excision of a breast lesion (19110-19126), and placement of breast localization devices (19281-19288).

Surgical Treatments and Mastectomy Procedures

Surgical intervention remains a cornerstone of breast cancer treatment, ranging from breast-conserving surgery to more extensive mastectomy procedures. Code 19301 (Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy))describes a partial mastectomy (also known as a lumpectomy, quadrantectomy, or segmentectomy) where only a portion of the ipsilateral breast tissue is removed. When axillary lymphadenectomy is also performed, report 19302 (Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy). These approaches are considered breast-conserving or breast-sparing surgeries.

For total removal of the ipsilateral breast tissue, report 19303 (Mastectomy, simple, complete). This includes mastectomy procedures with or without skin or nipple preservation, excluding excision of pectoral muscles or lymph nodes. Code 19300 (Mastectomy for gynecomastia) describes a total mastectomy specifically for gynecomastia.

Codes 19305-19307 describe radical, or total, mastectomy with removal of the nipple, pectoral muscles, and lymph nodes. Modified radical mastectomy is reported with code 19307. For bilateral mastectomy procedures (19300-19307), you’ll append modifier 50 (Bilateral procedure).

Breast reconstruction may be performed immediately or delayed; codes 19340 (Insertion of breast implant on same day of mastectomy (ie, immediate) and 19357 (Tissue expander placement in breast reconstruction, including subsequent expansion(s)) describe immediate reconstruction with breast implant or tissue expander. Reconstruction using autologous tissue with skin grafts may also be an option, and 19361-19369 describe reconstruction, depending on the technique and donor site used.

Chemotherapy Coding

Chemotherapy administration requires careful attention to drug codes, administration methods, and duration. CPT^® codes 96413-96417 cover chemotherapy administration through intravenous push or infusion methods.

Common chemotherapy regimens include AC (doxorubicin and cyclophosphamide), TC (docetaxel and cyclophosphamide), and AC-T (doxorubicin, cyclophosphamide followed by paclitaxel). These regimens are selected based on tumor subtype, stage, and patient-specific factors, such as hormone receptor status and HER2 expression. Each drug requires specific HCPCS Level II codes, such as J9000 (Injection, doxorubicin hydrochloride, 10 mg).

In early-stage, hormone receptor–positive, HER2-negative breast cancer, genomic assays such as the Oncotype DX Breast Recurrence Score^® test (81518–81523) measure tumor mRNA expression to generate a recurrence score. These results help predict the risk of recurrence and whether chemotherapy is likely to provide meaningful benefit, allowing many patients to avoid unnecessary treatment.

Radiation Oncology Therapy

Radiation therapy is a standard of care for early-stage breast cancer after breast-conserving surgery and is typically used after surgery to destroy remaining cancer cells and reduce the risk of recurrence. It delivers high-energy radiation to the breast, chest wall, or nearby lymph nodes to target cancer while sparing healthy tissue.

The most common technique used is external beam radiation therapy (EBRT), particularly 3D conformal radiation therapy, which shapes radiation beams to match the tumor area. Hypofractionated radiation therapy, which uses higher doses over fewer sessions, has become the preferred schedule for many patients, offering similar outcomes with greater convenience. According to institutions like MD Anderson Cancer Center and NCCN guidelines, advanced techniques such as IMRT are typically reserved for special cases involving complex anatomy or prior radiation.

From a coding perspective, radiation therapy includes planning, delivery, and management phases. You can find he relevant codes in Chapter 7 of the CPT^® code book, primarily in the 77261-77799 range. Accurate coding reflects the method, complexity, and technology used during treatment.

Immunotherapy and Targeted Therapy

Modern breast cancer treatment increasingly includes immunotherapy and targeted therapies, which require specialized coding knowledge due to their complexity and evolving usage. For example, trastuzumab (Herceptin), used in HER2-positive breast cancers, is billed with J9355 and pertuzumab (Perjeta) is billed with J9306.

Immunotherapy agents such as pembrolizumab (Keytruda) are billed with J9271, and newer antibody-drug conjugates like ado-trastuzumab emtansine (Kadcyla) are billed with J9354. These treatments often involve complex administration schedules, multiple cycles, and weight-based or flat dosing, making precise documentation and code selection critical for accurate reimbursement.

Hormone Therapy

Hormone therapy is a standard treatment for hormone receptor-positive (HR+) breast cancer. It works by blocking estrogen receptors or lowering estrogen levels to slow or stop cancer growth. Common oral medications include tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors such as anastrozole, letrozole, and exemestane. These drugs are typically filled through pharmacies and are not billed using CPT^® or HCPCS Level II codes in outpatient settings. Injectable agents like leuprolide (Lupron) and goserelin (Zoladex), used for ovarian suppression in premenopausal patients, are billed with J9217 and J9202 respectively. Diagnosis coding should include the breast cancer code and Z17.0 (Estrogen receptor positive status [ER+]) to indicate estrogen receptor positivity, supporting medical necessity and treatment planning.

Looking Forward

As medical coders, understanding the nuances of breast cancer diagnosis, screening, and procedure coding options and treatment modalities enables us to contribute meaningfully to improved patient outcomes. Breast cancer care is continually advancing with new developments in precision medicine, genomic testing, and targeted therapies. Staying informed about coding changes, clinical guidelines, and evolving treatments helps us remain effective and trusted members of the care team.

As both a healthcare business professional and a breast cancer survivor, I know firsthand the importance of awareness, early detection, and accurate documentation for coding. Behind every code is a patient’s story, and getting it right matters.

Resources

American Cancer Society. Breast Cancer Statistics. How Common Is Breast Cancer?
American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025
American College of Radiology. ACR Appropriateness Criteria Female Breast Cancer Screening.
Feel For Your Life Foundation. Feel For Your Life Mobile Application.
Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2024. CA Cancer J Clin. 2024;74(5):398-427.
National Comprehensive Cancer Network. >Breast Cancer Screening and Diagnosis.
Susan G. Komen Foundation. Breast Cancer Screening Recommendations for Women at Average Risk.
Susan G. Komen Foundation. Breast Cancer Screening Tests and Recommendations.
Susan G. Komen Foundation. Breast Cancer Screening Tests for Women at Higher Risk.

Laura Manser, CPC, CPCO, CDEO, CPMA, CEMC, CIRCC, RCC
(A version of this article first appeared in the October 2025 issue of AAPC the Magazine)